Abstract: The present invention discloses compositions of novel DYRK1A protein inhibitors based on a 3,5-diarylazaindole motif and their preparation and use as medications in the treatment of cognitive disorders associated with dysfunction of DYRK1A protein, with Down's syndrome and with Alzheimer's disease.

Abstract: The present invention relates to a compound of formula (I?) or a pharmaceutically acceptable salt, solvate or hydrate thereof, in which: X3 is F, OH or SH, Y3 is F, OH or SH, X1, X2, X4, X5, Y1, Y2, Y4 and Y5 are, independently of one another, H, F, Cl, Br, OH or SH, and 1 to 2 groups among the X1, X2, X4 and X5 radicals are other than H and/or 1 to 2 groups among the Y1, Y2, Y4 and Y5 radicals are other than H. The present invention also relates to a compound of formula (I?) for use as a medicament, in particular in the prevention and/or treatment of cognitive disorders associated with a dysfunction of the Dyrk1A protein.